Loading
A phase 3 trial of Megestrol acetate in non-small-cell lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., now recruiting.
Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07150663 by Changchun GeneScience Pharmaceutical Co., Ltd., with 134 participants planned, started 2025-08-20 and due to reach its primary completion in 2027-06-30. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Megestrol acetate and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/